The Boston-based company plans to market 11.8 million shares for $16 to $18 each, according to its filing Thursday with the US Securities and Exchange Commission.
At the top of that range, Avalyn would have a market value of $665 million based on the outstanding shares listed in its filing.
The company’s pipeline is focused on treating pulmonary fibrosis, a disease with a median survival rate of three to five years, the filing shows.
Avalyn counts ...